Ads
related to: duchenne muscular dystrophy drugs
Search results
Results From The WOW.Com Content Network
The U.S. FDA has approved privately held Italfarmaco Group's drug to treat Duchenne muscular dystrophy (DMD), an inherited muscle-wasting disorder, the health regulator said on Thursday. The oral ...
In May 2014, ataluren received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) [18] and received market authorization from the European Commission to treat people with nonsense mutation Duchenne muscular dystrophy in August 2014; [2] a confirmatory phase III clinical trial ...
Duchenne muscular dystrophy is a rare progressive disease that eventually affects all voluntary muscles and involves the heart and breathing muscles in later stages. Life expectancy is estimated to be around 25–26, [18] [59] but this varies. People born with Duchenne muscular dystrophy after 1990 have a median life expectancy of approximately ...
(Reuters) -The U.S. Food and Drug Administration allowed the expanded use of Sarepta Therapeutics' gene therapy for patients with Duchenne muscular dystrophy aged four and older on Thursday ...
Givinostat is in numerous phase II clinical trials (including for relapsed leukemias and myelomas), [15] and has been granted orphan drug designation in the European Union for the treatment of systemic juvenile idiopathic arthritis, [16] polycythaemia vera. [11] and Duchenne muscular dystrophy.
(Reuters) -Catalyst Pharmaceuticals said on Thursday that U.S. health regulators have approved its partner Santhera Pharmaceuticals' drug to treat Duchenne muscular dystrophy (DMD) in patients ...
Ads
related to: duchenne muscular dystrophy drugs